SG Americas Securities LLC Has $1.26 Million Stock Position in Immunovant, Inc. (NASDAQ:IMVT)

SG Americas Securities LLC trimmed its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 69.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 29,937 shares of the company's stock after selling 66,766 shares during the period. SG Americas Securities LLC's holdings in Immunovant were worth $1,261,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. AWM Investment Company Inc. purchased a new stake in shares of Immunovant during the 3rd quarter valued at $1,920,000. Wellington Management Group LLP bought a new position in shares of Immunovant in the third quarter worth approximately $6,473,000. Citigroup Inc. lifted its position in Immunovant by 43.3% during the third quarter. Citigroup Inc. now owns 126,316 shares of the company's stock valued at $4,849,000 after purchasing an additional 38,179 shares during the period. Principal Financial Group Inc. lifted its position in Immunovant by 1,299.7% during the third quarter. Principal Financial Group Inc. now owns 327,075 shares of the company's stock valued at $12,556,000 after purchasing an additional 303,707 shares during the period. Finally, Trexquant Investment LP bought a new position in Immunovant during the third quarter valued at approximately $2,987,000. 47.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

IMVT has been the subject of several research analyst reports. HC Wainwright raised their target price on shares of Immunovant from $47.00 to $51.00 and gave the company a "buy" rating in a research note on Thursday, December 21st. UBS Group lifted their price objective on shares of Immunovant from $55.00 to $56.00 and gave the company a "buy" rating in a research note on Friday, December 1st. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immunovant in a report on Tuesday, December 12th. They issued a "buy" rating and a $50.00 price target for the company. JPMorgan Chase & Co. initiated coverage on shares of Immunovant in a report on Tuesday, February 20th. They set an "overweight" rating and a $51.00 target price for the company. Finally, The Goldman Sachs Group started coverage on shares of Immunovant in a research report on Wednesday, March 13th. They issued a "buy" rating and a $50.00 target price on the stock. Seventeen equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunovant presently has an average rating of "Buy" and a consensus price target of $48.00.

Insider Transactions at Immunovant

In other news, insider Mark S. Levine sold 2,134 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $36.15, for a total transaction of $77,144.10. Following the sale, the insider now directly owns 301,968 shares of the company's stock, valued at approximately $10,916,143.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider Mark S. Levine sold 2,134 shares of the firm's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $36.15, for a total transaction of $77,144.10. Following the completion of the transaction, the insider now directly owns 301,968 shares in the company, valued at $10,916,143.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Eva Renee Barnett sold 3,515 shares of the firm's stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $41.83, for a total value of $147,032.45. Following the transaction, the chief financial officer now owns 323,350 shares of the company's stock, valued at $13,525,730.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 17,151 shares of company stock valued at $659,896. 4.80% of the stock is owned by corporate insiders.

Immunovant Stock Down 0.6 %

Shares of IMVT traded down $0.21 on Friday, hitting $32.31. The company's stock had a trading volume of 1,260,187 shares, compared to its average volume of 1,290,489. The firm's fifty day moving average price is $35.07 and its 200-day moving average price is $35.71. Immunovant, Inc. has a fifty-two week low of $14.05 and a fifty-two week high of $45.58. The firm has a market capitalization of $4.69 billion, a price-to-earnings ratio of -17.56 and a beta of 0.67.

Immunovant (NASDAQ:IMVT - Get Free Report) last announced its quarterly earnings data on Monday, February 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. As a group, equities analysts predict that Immunovant, Inc. will post -1.7 earnings per share for the current fiscal year.

Immunovant Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.